Sriram Venneti
Professor
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (7)
Contains supplementary data and table titles and as well as supplementary figures with associated titles and legends.Fig. S1. Selection method for planned efficacy analysis of ONC201 in patients with H3K27MDMG.Fig. S2. Progression-free survival from diagnosis of trial patients with non-recurrent H3K27MDMG treated with ONC201.Fig. S3. Swimmers’ plot of ONC201 response by recurrence status, tumor location, and ONC201 trial.Fig. S4. ONC201 efficacy is independent of TP53 mutation status and chromosomal instability.Fig. S5. Cox proportional hazard regression to assess the effect of ONC201 after adjusting for confounders.Fig. S6. Survival of patients with H3K27M-DMG treated with ONC201 versus ONC201untreated historical controls.Fig. S7. Survival of patients with H3K27M-DMG treated with ONC201 versus ONC201untreated patients (PNOC003 or HERBY Phase II trials).Fig. S8. Molecular attributes of patients with H3K27M-DMG treated with ONC201.Fig. S9: Survival of H3K27M-DMG mice models treated with ONC201.Fig. S10. Integrative analysis of in vitro and human tumor metabolic gene expression in response to ONC201.Fig. S11. ONC201-mediated L2HG production increases H3K27me3 in H3K27M-DMG cells.Fig. S12. ONC201-induced increase in H3K27me3 is mediated by lactate dehydrogenase.Fig. S13. ONC201 alters genomic chromatin accessibility and H3K27ac distribution in H3K27M-DMG cells.Fig. S14. ONC201 increases global H3K27me3 in patient samples.Fig. S15. ONC201 does not cause hypermethylation leading to a glioma CpG island methylator phenotype.
Year:
2025
Patients with H3K27M-mutant diffuse midline glioma (DMG) have no proven effective therapies. ONC201 has recently demonstrated efficacy in these patients, but the mechanism behind this finding remains unknown. We assessed clinical outcomes, tumor sequencing, and tissue/cerebrospinal fluid (CSF) correlate samples from patients treated in two completed multisite clinical studies. Patients treated with ONC201 following initial radiation but prior to recurrence demonstrated a median overall survival of 21.7 months, whereas those treated after recurrence had a median overall survival of 9.3 months. Radiographic response was associated with increased expression of key tricarboxylic acid cycle–related genes in baseline tumor sequencing. ONC201 treatment increased 2-hydroxyglutarate levels in cultured H3K27M-DMG cells and patient CSF samples. This corresponded with increases in repressive H3K27me3 in vitro and in human tumors accompanied by epigenetic downregulation of cell cycle regulation and neuroglial differentiation genes. Overall, ONC201 demonstrates efficacy in H3K27M-DMG by disrupting integrated metabolic and epigenetic pathways and reversing pathognomonic H3K27me3 reduction. Significance: The clinical, radiographic, and molecular analyses included in this study demonstrate the efficacy of ONC201 in H3K27M-mutant DMG and support ONC201 as the first monotherapy to improve outcomes in H3K27M-mutant DMG beyond radiation. Mechanistically, ONC201 disrupts integrated metabolic and epigenetic pathways and reverses pathognomonic H3K27me3 reduction. This article is featured in Selected Articles from This Issue, p. 2293
Year:
2025
Adrenocortical carcinoma (ACC) is a rare cancer in which tissue-specific differentiation is paradoxically associated with dismal outcomes. The differentiated ACC subtype CIMP-high is prevalent, incurable, and routinely fatal. CIMP-high ACC possess abnormal DNA methylation and frequent β-catenin–activating mutations. Here, we demonstrated that ACC differentiation is maintained by a balance between nuclear, tissue-specific β-catenin–containing complexes, and the epigenome. On chromatin, β-catenin bound master adrenal transcription factor SF1 and hijacked the adrenocortical super-enhancer landscape to maintain differentiation in CIMP-high ACC; off chromatin, β-catenin bound histone methyltransferase EZH2. SF1/β-catenin and EZH2/β-catenin complexes present in normal adrenals persisted through all phases of ACC evolution. Pharmacologic EZH2 inhibition in CIMP-high ACC expelled SF1/β-catenin from chromatin and favored EZH2/β-catenin assembly, erasing differentiation and restraining cancer growth in vitro and in vivo . These studies illustrate how tissue-specific programs shape oncogene selection, surreptitiously encoding targetable therapeutic vulnerabilities. Significance: Oncogenic β-catenin can use tissue-specific partners to regulate cellular differentiation programs that can be reversed by epigenetic therapies, identifying epigenetic control of differentiation as a viable target for β-catenin–driven cancers.
Year:
2025
Contains supplementary data and table titles and as well as supplementary figures with associated titles and legends. Fig. S1. Selection method for planned efficacy analysis of ONC201 in patients with H3K27MDMG. Fig. S2. Progression-free survival from diagnosis of trial patients with non-recurrent H3K27MDMG treated with ONC201. Fig. S3. Swimmers’ plot of ONC201 response by recurrence status, tumor location, and ONC201 trial. Fig. S4. ONC201 efficacy is independent of TP53 mutation status and chromosomal instability. Fig. S5. Cox proportional hazard regression to assess the effect of ONC201 after adjusting for confounders. Fig. S6. Survival of patients with H3K27M-DMG treated with ONC201 versus ONC201untreated historical controls. Fig. S7. Survival of patients with H3K27M-DMG treated with ONC201 versus ONC201untreated patients (PNOC003 or HERBY Phase II trials). Fig. S8. Molecular attributes of patients with H3K27M-DMG treated with ONC201. Fig. S9: Survival of H3K27M-DMG mice models treated with ONC201. Fig. S10. Integrative analysis of in vitro and human tumor metabolic gene expression in response to ONC201. Fig. S11. ONC201-mediated L2HG production increases H3K27me3 in H3K27M-DMG cells. Fig. S12. ONC201-induced increase in H3K27me3 is mediated by lactate dehydrogenase. Fig. S13. ONC201 alters genomic chromatin accessibility and H3K27ac distribution in H3K27M-DMG cells. Fig. S14. ONC201 increases global H3K27me3 in patient samples. Fig. S15. ONC201 does not cause hypermethylation leading to a glioma CpG island methylator phenotype.
Year:
2024
Contains supplementary data and table titles and as well as supplementary figures with associated titles and legends. Fig. S1. Selection method for planned efficacy analysis of ONC201 in patients with H3K27MDMG. Fig. S2. Progression-free survival from diagnosis of trial patients with non-recurrent H3K27MDMG treated with ONC201. Fig. S3. Swimmers’ plot of ONC201 response by recurrence status, tumor location, and ONC201 trial. Fig. S4. ONC201 efficacy is independent of TP53 mutation status and chromosomal instability. Fig. S5. Cox proportional hazard regression to assess the effect of ONC201 after adjusting for confounders. Fig. S6. Survival of patients with H3K27M-DMG treated with ONC201 versus ONC201untreated historical controls. Fig. S7. Survival of patients with H3K27M-DMG treated with ONC201 versus ONC201untreated patients (PNOC003 or HERBY Phase II trials). Fig. S8. Molecular attributes of patients with H3K27M-DMG treated with ONC201. Fig. S9: Survival of H3K27M-DMG mice models treated with ONC201. Fig. S10. Integrative analysis of in vitro and human tumor metabolic gene expression in response to ONC201. Fig. S11. ONC201-mediated L2HG production increases H3K27me3 in H3K27M-DMG cells. Fig. S12. ONC201-induced increase in H3K27me3 is mediated by lactate dehydrogenase. Fig. S13. ONC201 alters genomic chromatin accessibility and H3K27ac distribution in H3K27M-DMG cells. Fig. S14. ONC201 increases global H3K27me3 in patient samples. Fig. S15. ONC201 does not cause hypermethylation leading to a glioma CpG island methylator phenotype.
Year:
2024
Adrenocortical carcinoma (ACC) is a rare cancer in which tissue-specific differentiation is paradoxically associated with dismal outcomes. The differentiated ACC subtype CIMP-high is prevalent, incurable, and routinely fatal. CIMP-high ACC possess abnormal DNA methylation and frequent β-catenin activating mutations. Here, we demonstrated that ACC differentiation is maintained by a balance between nuclear, tissue-specific β-catenin-containing complexes and the epigenome. On chromatin, β-catenin bound master adrenal transcription factor SF1 and hijacked the adrenocortical super-enhancer landscape to maintain differentiation in CIMP-high ACC; off chromatin, β-catenin bound histone methyltransferase EZH2. SF1/β-catenin and EZH2/β-catenin complexes present in normal adrenals persisted through all phases of ACC evolution. Pharmacologic EZH2 inhibition in CIMP-high ACC expelled SF1/β-catenin from chromatin and favored EZH2/β-catenin assembly, erasing differentiation and restraining cancer growth in vitro and in vivo. These studies illustrate how tissue-specific programs shape oncogene selection, surreptitiously encoding targetable therapeutic vulnerabilities.
Year:
2024
H3K27M-mutant diffuse midline glioma (DMG) patients have no proven effective therapies. ONC201 has recently demonstrated efficacy in these patients, but the mechanism behind this remains unknown. We assessed clinical outcomes, tumor sequencing, and tissue/CSF correlate samples from patients treated in two completed multi-site clinical studies. Patients treated with ONC201 following initial radiation but prior to recurrence demonstrated a median overall survival of 21.7 months, while those treated after recurrence had a median overall survival of 9.3 months. Radiographic response was associated with increased expression of key tricarboxylic acid cycle-related genes in baseline tumor sequencing. ONC201 treatment increased 2-hydroxyglutarate levels in cultured H3K27M-DMG cells and patient CSF samples. This corresponded with increases in repressive H3K27me3 in vitro and in human tumors accompanied by epigenetic downregulation of cell cycle regulation and neuro-glial differentiation genes. Overall, ONC201 demonstrates efficacy in H3K27M-DMG by disrupting integrated metabolic and epigenetic pathways and reversing pathognomonic H3K27me3 reduction.
Year:
2024
Collaborators (38)
Matthew Hall
Associate Clinical Professor
Florida International University
Chandan Kumar
Associate Research Scientist
University of Michigan
Berenice Bilharinho de Mendonca
Professor of Endocrinology
University of Sao Paulo
Adam Resnick
Director
University of Pennsylvania
Sebastian Waszak
Tenure Track Assistant Professor
University of California, San Francisco
Mariella Filbin
Dana-Farber Cancer Institute
Arul M Chinnaiyan
University of Michigan
Yoshie Umemura
Barrow Neurological Institute
Rajen J. Mody
University of Michigan
minesh mehta
Chair
Florida International University
Anna Schwendeman
-
Timothy Cloughesy
Director of NeuroOncology Program/Professor
Ronald Reagan UCLA Medical Center
Michelle M Kim
University of Michigan
Lili Zhao
Professor
Northwestern University
Charles Burant
University of Michigan
Sabine Mueller
Adjunt Associate Professor
University of California
Nathalie Agar
Principal Investigator
Brigham and Women's Hospital
Tobias Else
University of Michigan
Rajan Jain
Professor
NYU Langone Health
Matthew Dun
Professor Paediatric Heamatology/Oncology Research
Hunter Medical Research Institute
Antonio Marcondes Lerario
University of Michigan
Susanne Schmidt
Group Leader
University of Bonn
Carl Koschmann
University of Michigan Medical School
Andrea T. Franson
-
Javad Nazarian
Lead, DMG Research Center
-
William E Rainey
University of Michigan
Chan Chung
Principal investigator
Daegu Gyeongbuk Institute of Science and Technology
Richard J Auchus
University of Michigan
Benjamin M Ellingson
Professor
University of California, Los Angeles
David breault
Harvard University
Derek Dang
University of Michigan
Thomas Giordano
Professor
University of Michigan
Christopher LaPensee
University of Michigan
Daniel R. Wahl
University of Michigan
Gary D. Hammer
University of Michigan
Jacques Grill
Head day care
Gustave Roussy
Costas A. Lyssiotis
University of Michigan
Sharon L Gardner
Associate Professor (Clinical) of Pediatrics
NYU School of Medicine
Make your next move.
Prepare your application
Review drafts before you send them.